Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,755.17
(
0.65%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

WorstLuck

Send PM Follow Ignore
Followers 15
Posts 1617
Boards Moderated 0
Alias Born 02/23/2010

WorstLuck

Re: willyw post# 198676

Wednesday, 12/30/2015 1:15:57 PM

Wednesday, December 30, 2015 1:15:57 PM

Post# of 257302

To which I might add, marketing....



The secondary endpoints are all about marketing and market share for sure. Showing superiority does that.

The primary endpoint is all about getting to market in the first place. Approval is still the name of the game. The business decision (whether guided by the FDA or not) to do it as non-inferiority may have been (and I suspect is) the safest path to approval.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up